Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience

被引：0
|
作者：
Leibowitz-Amit, Raya
Atenafu, Eshetu G.
Seah, Jo-An
Templeton, Arnoud J.
Vera-Badillo, Francisco Emilio
Solow, Henry L.
Knox, Jennifer J.
Sridhar, Srikala S.
Tannock, Ian
Joshua, Anthony Michael
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.61
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
61
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.
    Al-Ezzi, Esmail M.
    Abdeljalil, Osama
    Lajkosz, Katherine
    Gramolini, Shreya S.
    Mejia, Nely Mercy Diaz
    Alqaisi, Husam
    Peng, Jenny
    O'Dwyer, Richard Thomas
    Alghamdi, Mohammed
    Almuthri, Sulaiman
    Kumar, Vikaash
    Jiang, Di Maria
    Fallah-Rad, Nazanin
    Sridhar, Srikala S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 179 - 179
  • [42] The development of abiraterone acetate for castration-resistant prostate cancer
    Grist, Emily
    Attard, Gerhardt
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (06) : 289 - 294
  • [43] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Salem, Mohamed
    Garcia, Jorge A.
    [J]. CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 92 - 96
  • [44] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [45] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Mohamed Salem
    Jorge A. Garcia
    [J]. Current Oncology Reports, 2011, 13 : 92 - 96
  • [46] Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Lily P. H. Yang
    Katherine A. Lyseng-Williamson
    [J]. Drugs & Aging, 2012, 29 : 243 - 248
  • [47] Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone
    Duarte, C.
    Jimeno, A.
    Kessler, E. R.
    [J]. DRUGS OF TODAY, 2019, 55 (01) : 5 - 15
  • [48] New drugs in the treatment of metastatic castration-resistant prostate cancer: abiraterone acetate
    Martinez-Hernandez, Lucia
    Martinez-Prieto, Marcela
    Galvan-Salazar, Gabriel
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2013, 12 (01): : 32 - 40
  • [49] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
    Martini, Alberto
    Fallara, Giuseppe
    Ploussard, Guillaume
    Malavaud, Bernard
    [J]. LANCET ONCOLOGY, 2023, 24 (10): : 1056 - 1057
12345